Lipinski's rule of five

Lipinski's Rule of Five is a set of guidelines designed to predict the oral bioavailability of a compound, particularly in the context of drug development. Formulated by Christopher A. Lipinski in 1997, these rules help assess whether a small molecule is likely to have favorable pharmacokinetics in humans (i.e., absorption, distribution, metabolism, and excretion or ADME properties).